IDIOPATHIC INFLAMMATORY MYOPATHIES

This study tests a drug that blocks a key immune signal (JAK1) in people with Behçet's disease, myositis, or IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term steroids. About 60 adults will take the drug and be monitored…

This early-stage trial tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The main goal is to see if the treatment is safe and tolerable. Researchers will also check if it helps control the…

This study tests a new treatment using specially engineered immune cells (CAR-T) to target and calm overactive immune cells in people with autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. About 20 adults aged 18 to 70 with active disease will receive either CD…

This early-stage trial tests a new treatment called AZD0120 for people with certain autoimmune diseases like systemic sclerosis, myositis, or hard-to-treat rheumatoid arthritis. AZD0120 uses a patient's own immune cells, which are modified in a lab to target and attack faulty imm…

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can help people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive the treatment and be mo…

This early-stage study tests whether a new drug called AZD5492 is safe and tolerable in adults with lupus, myositis, or rheumatoid arthritis. About 72 participants will receive either one or two doses of the drug and be monitored for side effects over 6 months. The goal is to gat…

This study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (IIM), a group of diseases causing muscle inflammation and weakness. About 123 adults aged 18 to 75 who haven't improved with standard therapies will be rando…

This early-stage study tests a new drug called XmAb657 in healthy volunteers and people with autoimmune diseases like scleroderma, Sjögren's, and inflammatory myopathies. The main goal is to see if the drug is safe and tolerable when given as an injection under the skin. Up to 60…

This study tests a new treatment called NKX019, made from donor immune cells engineered to target and calm overactive immune cells. It is for people with certain autoimmune diseases like systemic sclerosis, inflammatory myopathies, or vasculitis. The goal is to see if it is safe …